Q2 Results Review: 66% companies see EPS cut, small and midcaps hit hard; PSBs, pharma shine
Q2 Results Review: 66% of companies reported EPS downgrades for FY25. Among these, 40% saw EPS reductions exceeding 3%, 29% ...